Furthermore, clinical studies demonstrated the significance of blocking the CD47/SIRP interaction in animals bearing xenograft models with a variety of hematological cancers, such as acute myeloid leukemia, myelodysplastic syndrome, and refractory non-Hodgkin lymphoma (47, 97, 124, 177, 200, 210). This evidence concerns the gene SIRPA and hematopoietic and lymphoid cell neoplasm.